首页 > 资讯 > Cell Reports Medicine出版物展示了Gelesis的口服治疗水凝胶如何在临床前研究中通过靶向肠肝轴促进减肥和代谢健康

Cell Reports Medicine出版物展示了Gelesis的口服治疗水凝胶如何在临床前研究中通过靶向肠肝轴促进减肥和代谢健康

泰然健康网
2024-12-28 22:52

BOSTON--(BUSINESS WIRE)--A new paper published today in Cell Reports Medicine suggests that weight loss resulting from Gelesis’ superabsorbent hydrogel treatment is not only a result of its space-occupying properties; the mechanical composition and structure of the material may have notable benefits for gut and metabolic health..

BOSTON-（BUSINESS WIRE）-今天在Cell Reports Medicine上发表的一篇新论文表明，Gelesis的超吸收性水凝胶处理导致的体重减轻不仅是其占位特性的结果；材料的机械组成和结构可能对肠道和代谢健康具有显着益处。。

The continued rise in obesity and type 2 diabetes has led to the increasing prevalence of fatty liver disease worldwide and highlights the urgent need for therapies that can address the problem. Diets rich in fat, sugars, and ultra-processed foods are a contributor to rising obesity rates. These high fat/high carb diets have profound negative impacts on the host gut barrier function and microbial structure.

肥胖和2型糖尿病的持续增加导致全世界脂肪肝疾病的患病率增加，并强调迫切需要能够解决该问题的治疗方法。富含脂肪，糖和超加工食品的饮食是导致肥胖率上升的原因。这些高脂肪/高碳水化合物饮食对宿主肠道屏障功能和微生物结构具有深远的负面影响。

This in turn has a detrimental effect and can lead to increased gut permeability and higher instances of metabolic disorders like obesity, diabetes, and fatty liver..

这反过来又会产生不利影响，并可能导致肠道通透性增加和肥胖，糖尿病和脂肪肝等代谢紊乱的发生率增加。。

The reported studies examined both the efficacy and mechanism of action of Gelesis’ oral superabsorbent hydrogels (OSH) in preclinical models of diet-induced obesity, metabolic syndrome, and NASH. The Gelesis OSH consistently resulted in weight loss, improved insulin sensitivity, and prevented the progression of NAFLD..

报道的研究检查了Gelesis口服超吸收性水凝胶（OSH）在饮食诱导的肥胖，代谢综合征和NASH的临床前模型中的功效和作用机制。Gelesis OSH始终如一地导致体重减轻，改善胰岛素敏感性，并阻止NAFLD的进展。。

Notably, the hydrogel induced endogenous GLP-1 and rapid, unique, and consistent changes in the gut microbiota, specifically fostering the growth of Akkermansia muciniphila, which is thought to be a beneficial microbe for metabolic disorders. Through comparison with supplement fiber (inulin, psyllium and hydrogels with different mechanical properties) it demonstrated that the physical structure of the hydrogel had the unique capability to boost Akkermansia growth.

值得注意的是，水凝胶诱导内源性GLP-1和肠道微生物群的快速，独特和一致的变化，特别是促进Akkermansia muciniphila的生长，其被认为是代谢紊乱的有益微生物。通过与补充纤维（菊粉，车前子和具有不同机械性能的水凝胶）的比较，证明水凝胶的物理结构具有促进Akkermansia生长的独特能力。

The study also demonstrated that the beneficial metabolic effects were independent of the weight loss effect..

该研究还表明，有益的代谢作用与体重减轻作用无关。。

“It was exciting to see how specific structural and physical properties are important for achieving the therapeutic effect on the gut microbiota, and how hydrogel-dependent preservation of the gut barrier properties is improving insulin sensitivity, promoting liver health and inducing weight loss,” said Maria Rescigno, PhD, professor at Humanitas University, group leader at Humanitas Research Hospital in Milan and senior author of the paper.

“令人兴奋的是，看看具体的结构和物理特性对于实现对肠道微生物群的治疗效果是多么重要，以及水凝胶依赖性保存肠道屏障特性如何改善胰岛素敏感性，促进肝脏健康和诱导体重减轻，”人文大学教授Maria Rescigno博士说，米兰Humanitas研究医院组长和该论文的高级作者。

“Our work shows the potential of oral superabsorbent hydrogels to be an effective and non-invasive therapeutic tool in the long-term treatment of obesity and metabolic disorders.”.

“我们的工作表明口服超吸收性水凝胶有可能成为长期治疗肥胖和代谢紊乱的有效和非侵入性治疗工具。”。

Read the full paper in Cell Reports Medicine here.

在这里阅读Cell Reports Medicine的全文。

Gelesis Holdings Inc. (“Gelesis”) is a consumer-centered biotherapeutics company and the maker of Plenity®, which is inspired by nature and FDA cleared to aid in weight management. Our first-of-their-kind non-systemic superabsorbent hydrogels are made entirely from naturally derived building blocks.

Gelesis Holdings Inc.（“Gelesis”）是一家以消费者为中心的生物治疗公司，也是Plenity®的制造商，该公司受到nature和FDA的启发，可以帮助进行体重管理。我们的第一种非系统性超吸收性水凝胶完全由天然衍生的结构单元制成。

They are inspired by the composition and mechanical properties of raw vegetables, taken by capsule, and act locally in the digestive system, so people feel satisfied with smaller portions. Our portfolio includes Plenity® and potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

它们受到生蔬菜的成分和机械性能的启发，由胶囊摄取，并在消化系统中局部起作用，因此人们对较小的部分感到满意。我们的产品组合包括针对2型糖尿病，非酒精性脂肪性肝病（NAFLD）/非酒精性脂肪性肝炎（NASH）和功能性便秘患者开发的Plenity®和潜在疗法。

For more information, visit gelesis.com, or connect with us on X, formerly known as Twitter: @GelesisInc..

欲了解更多信息，请访问gelesis.com，或在X（以前称为Twitter:@GelesisInc。）上与我们联系。。

Plenity® is indicated to aid weight management in adults with excess weight or obesity, a Body Mass Index (BMI) of 25–40 kg/m², when used in conjunction with diet and exercise.

当与饮食和运动结合使用时，Plenity®有助于超重或肥胖成年人的体重管理，体重指数（BMI）为25-40 kg/m²。

Important Safety Information about Plenity

关于充分性的重要安全信息

Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity.

怀孕或对纤维素，柠檬酸，富马酸硬脂酸钠，明胶或二氧化钛过敏的患者不应服用丰满的药物。

To avoid impact on the absorption of medications:

避免影响药物的吸收：

For all medications that should be taken with food, take them after starting a meal.

对于所有应该与食物一起服用的药物，在开始用餐后服用。

For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician.

对于所有应该在没有食物的情况下服用的药物（空腹），继续空腹或按照医生的建议服用。

The overall incidence of side effects with Plenity was no different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence.

充分副作用的总发生率与安慰剂无差异。最常见的副作用是腹泻，腹部扩张，排便不频繁和肠胃气胀。

Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using Plenity until you can speak to your doctor.

如果出现问题，请立即联系医生。如果您有严重的过敏反应，严重的胃痛或严重的腹泻，请停止使用Plenuity，直到您可以与医生交谈。

Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.

仅限Rx。为了安全和正确使用完整性或更多信息，请与医疗保健专业人员交谈，阅读患者使用说明，或致电1-844-Plenity。

Forward-Looking Statements

前瞻性声明

Certain statements, estimates, targets and projections in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. The words “anticipate,” “believe,” continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

本新闻稿中的某些陈述，估计，目标和预测可能构成联邦证券法含义内的“前瞻性陈述”。“预期”，“相信”，“继续”，“可以”，“估计”，“期望”，“打算”，“可以”，“可能”，“计划”，“可能”，“潜力”，“预测”，“项目”，“应该”，“努力”，“将会”等词语可以识别前瞻性陈述，但缺少这些词语并不意味着该陈述不是前瞻性的。

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Gelesis’ or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to Gelesis’ expected operating and financial performance and market opportunities.

前瞻性陈述是基于当前预期和假设的关于未来事件的预测，预测和其他陈述，因此受到风险和不确定性的影响。前瞻性陈述包括但不限于关于Gelesis'或其管理团队对未来的期望，希望，信念，意图或策略的陈述，包括与Gelesis的预期运营和财务绩效以及市场机会相关的陈述。

In addition, any statements that refer to guidance, projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Gelesis assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

此外，任何涉及未来事件或情况的指导，预测，预测或其他特征（包括任何基本假设）的陈述都是前瞻性陈述。前瞻性陈述仅在其作出之日才发表。警告读者不要过分依赖前瞻性陈述，Gelesis不承担任何义务，也不打算更新或修改这些前瞻性陈述，无论是由于新信息，未来事件还是其他原因。

Gelesis gives no assurance that any expectations set forth in this press release will be achieved. Various risks and uncertainties (some of which are beyond Gelesis’ control) or other factors could cause actual future results, performance or events to.

Gelesis不能保证本新闻稿中提出的任何期望都会实现。各种风险和不确定性（其中一些超出了Gelesis的控制范围）或其他因素可能导致实际的未来结果，表现或事件。